- Drug delivery platform developer Lexaria Bioscience recently received its 20th patent — granted in Japan for beverages with lipophilic active agents
- The active agents include non-psychoactive cannabinoids and over-the-counter NSAIDS such as ibuprofen and aspirin that target pain and inflammation
- Lexaria’s DehydraTECH platform transforms drugs into a powder or liquid form that maintains the drug’s efficacy and allows it to be assimilated by the body more rapidly than normal oral ingestion of pills
- The company will also announce the latest results from six key R&D projects focusing on concentration levels, tolerability and avoidance of incidental new molecular entities (“NMEs”) soon
Drug assimilation technology innovator Lexaria Bioscience (NASDAQ: LEXX) is demonstrating the versatility of its DehydraTECH platform with the announcement of a patent for “stable ready-to-drink beverage compositions comprising lipophilic active agents” — the company’s first granted in Japan.
“This new patent adds to our existing suite of granted patents spanning the EU, the U.S., India and Australia, and continues to build value for Lexaria shareholders and clients,” CEO Chris Bunka stated (https://ibn.fm/hHDZf).
The DehydraTECH technology converts drugs into a powder or liquid form that will make them orally ingestible at a level of quick absorption and efficacy that is competitive with smoked or vaporized drug use but without the risk of lung harm that may be a consequence of inhaling drugs.
Processing drugs with DehydraTECH is being further evaluated through the company’s research and development program to establish that the drugs do not undergo unexpected changes in the process that would affect their safe use, and Lexaria expects to report its latest findings among six key R&D projects in the coming months (https://ibn.fm/ck0U3).
The patent for beverage compositions with lipophilic active agents in Japan references active ingredients such as non-psychoactive cannabinoids and NSAIDS (ibuprofen, aspirin and similar OTC anti-inflammatory pain relievers).
According to the announcement, Lexaria has 13 patent families among its worldwide patent applications. The Japan patent is the third one granted in its third family, and the 20th patent overall.
Earlier this month, Lexaria announced its voluntary delisting of its common shares from the Canadian Securities Exchange (CSE ticker LXX) in order to focus its resources on the applied R&D programs, reduce fees and managerial requirements that came with a dual listing and to provide more liquidity for shareholders.
“Since Lexaria’s shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq,” the announcement states (https://ibn.fm/8kqL6).
In animal studies, DehydraTECH-delivered drugs have been shown to reach the bloodstream in minutes instead of hours, thanks to molecular delivery through the lymphatic system instead of the digestive system and its “first pass” liver exposure.
DehydraTECH thereby eliminates concerns about unwanted tastes and odors accompanying the medicines and increases bio-absorption of the partner drugs into blood circulation by 100 to 500 percent with even greater bio-absorption measured in brain tissue, which establishes the potential for advancing treatment of central nervous system disorders.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.